News

Tuesday, August 16, 2016

Three CardioCell-Sponsored Studies Reveal Results at the European Society of Cardiology (ESC) Congress 2016

“Hot Line” Late-Breaking Session Unveils Phase IIa Clinical Trial Results, While a Poster Session and a “Stem Cells & Cell Therapy” Session Share Pre-Clinical Study Data From the Application of CardioCell’s Stem Cells for Cardiovascular Indications

ROME, ITALY – EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – Aug. 16, 2016 – CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces results from three of its sponsored studies are accepted for presentation at ESC Congress. Each study – a Phase IIa clinical trial and two pre-clinical studies – applies CardioCell’s unique ischemia-tolerant mesenchymal stem cells (itMSCs) for cardiovascular indications. Visit the presentations as follows:  

“Hot Line” Late-Breaking Session: “Safety and efficacy of intravenous infusion of ischemia tolerant allogeneic mesenchymal stem cells in patients with non-ischemic cardiomyopathy”
When: Sunday, Aug. 28, 2016, from 12:12-12:22 p.m. CET
Where: Main Auditorium, Fiera di Roma
Presenter: Paper Co-Author Dr. Javed Butler, Chief of the Cardiology Division at Stony Brook University, Co-chair of CardioCell’s Heart Failure Advisory Board and Member of CardioCell’s Scientific Advisory Board
   
Poster Session 3: “Mesenchymal stem cells grown under chronic hypoxia improve LV function and inhibit adverse remodeling in mice with chronic ischemic cardiomyopathy”
When: Sunday, Aug. 28, 2016, from 2-6 p.m. CET
Where: Poster Area, Fiera di Roma
Presenter: Paper Co-Author Dr. Michael Lipinski, ‎Interventional Cardiologist at MedStar Washington Hospital Center
   
“Stem Cells & Cell Therapy” Session: “Mesenchymal stem cells grown under chronic hypoxia traffic to regions of myocardial infarction, suppress splenic natural killer cells, and attenuate adverse remodeling in mice with large acute MI”
When: Monday, Aug. 29, 2016, from 5:51-6 p.m. CET
Where: Agora 2 – Poster Area, Fiera di Roma
Presenter: Paper Co-Author Dr. Michael Lipinski, ‎Interventional Cardiologist at MedStar Washington Hospital Center

 About CardioCell LLC

Founded in San Diego, California, in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique, patented, ischemia-tolerant mesenchymal stem cells manufactured under cGMP conditions. CardioCell is a subsidiary of Stemedica Cell Technologies Inc., a global biotechnology company that manufactures adult allogeneic stem cells. The company’s technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in the United States, Europe and the former Soviet Union. CardioCell therapies offer a unique, proprietary technology based on the expansion of cells in constant hypoxia. The company has an exclusive, worldwide license from Stemedica to explore therapeutic indications for unmet cardiovascular needs, such as acute myocardial infarction, chronic heart failure and peripheral artery disease. For more information, visit www.stemcardiocell.com.  

About Stemedica Cell Technologies Inc.

Stemedica Cell Technologies Inc. is a global biopharmaceutical company that manufactures best-in-class allogeneic adult stem cells and stem cell factors. The company is a government licensed manufacturer of cGMP, clinical-grade stem cells currently used in US-based clinical trials for acute myocardial infarction, chronic heart failure, cutaneous photoaging, ischemic stroke, Alzheimer’s disease and traumatic brain injury. Stemedica’s products are also used on a worldwide basis by research institutions and hospitals for pre-clinical and clinical (human) trials. Stemedica is currently developing additional clinical trials for other medical indications using adult, allogeneic stems cell under the auspices of the FDA and other international regulatory institutions. The company is headquartered in San Diego, California, and can be found online at www.stemedica.com.